Lupin Digital Health's Lyfe Platform gets Class C Medical Device license from CDSCO
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-25 10:53 GMT | Update On 2024-04-25 10:53 GMT
Advertisement
Mumbai: Lupin Digital Health, India's evidence-based cardiology Digital Therapeutics (DTx) platform, has announced that its Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO).
"Having undergone a rigorous application, review, and on-site audit process, this Class C Medical Device license reaffirms the platform's effectiveness and emphasizes its commitment to quality, safety, and rigour.
Lupin Digital Health, a subsidiary of Lupin Limited, a leading global pharmaceutical company, developing advanced digital health solutions. Their primary offering, Lyfe, is a remote cardiac rehabilitation program powered by artificial intelligence (AI) and machine learning (ML). Through Digital Therapeutics, Lyfe offers health guidance, empowering individuals to manage their well-being proactively. With its integrated health monitoring devices, easy technological access, and the expertise of top cardiologists, Lyfe delivers a comprehensive cardiac care solution.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.